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Abstract 
In the pathogenesis of multiple sclerosis (MS), B cell/antibody-related mechanisms 
have recently received attention. To investigate the role of autoantibody in MS, we 
performed SEREX which can identify autoantibody cyclopedically. We identified 
serum antibodies against cytoskeletal protein talin1, and the levels of whom were 
remarkably higher in 39 MS than 43 normal controls (P <0.01) and 35 disease 
controls (P=0.06), and in MS patients without oligoclonal bands than ones with them. 
Moreover, we found the negative-correlations between serum anti-talin1 antibody and 
IgG index in MS (P =0.03). Anti-talin1 antibody exists in MS patients’ sera, which may 
have some protective factor.  
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1. Introduction 
MS is an immune-mediated disease characterized by demyelination of the CNS. It is 
believed that T cell autoreactivity against antigens expressed in the brain, particularly 
myelin antigens, plays a pivotal role in MS pathogenesis. In contrast, there is 
accumulated evidence that antibodies and B cells play a substantial role in MS 
pathogenesis, based on the following findings, at least, in a subgroup of MS patients: 
(a) deposition of immunoglobulins and complement activation in acute demyelinating 
lesions, an immunopathological pattern type II defined by Lucchinetti et al. 
(Lucchinetti et al., 2000); (b) efficacy of plasma exchange for acute exacerbations of 
MS patients (Weinshenker et al., 1999); (c) presence of CSF oligoclonal IgG bands in 
MS; (d) depletion of B cells by monoclonal antibodies has a considerable effect on 
disease activity in MS patients (Hauser et al., 2008). 
Although many components, including myelin-derived proteins and the potassium 
channel KIR4.1, are suspected as targets of autoantibodies, the real molecular targets 
which are necessary and sufficient for development of MS are unknown in MS (Lisak 
and Zweiman, 1977; Srivastava et al., 2012). Various antibody biomarkers for MS in 
the serum or CSF have been reported, but none of them are of practical use. 
Serological analysis of recombinant cDNA expression libraries (SEREX), an 
immunoscreening method that uses prokaryotically expressed cDNA libraries 
prepared from tissues or cell lines and sera from patients, is a very effective tool for 
identifying antigens recognized by spontaneous autoantibodies of patients with cancer 
and autoimmune diseases. Here, we elucidated whether there is a novel specific 
autoantibody in serum samples from MS patients using SEREX and amplified 
luminescence proximity homogeneous assay-linked immunosorbent assay 
(AlphaLISA) techniques and, if it exists, the role of the autoantibody in MS 
pathogenesis. 
 
2. Material and methods 
2.1. MS patient’s serum analyzed by SEREX  
The Local Ethical Review Board of the Graduate School of Medicine, Chiba University 
approved the study, and written informed consent was obtained from the patients and 
healthy volunteers. For immunoscreening by SEREX, serum was obtained from a 
27-year-old Japanese MS patient. She experienced an initial attack 6 years before 
serum sampling and dozens of attacks thereafter. Brain MRI showed multiple T2 
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hyperintense lesions fulfilling Barkhof criteria (Barkhof et al., 1997). She was treated 
with intravenous methylprednisolone therapy at most attacks but was never treated 
with disease modifying drugs. Her last attack started 14 days before serum sampling. 
At sampling, she did not receive any treatment. 
 
2.2. Phage cDNA library 
Double-stranded cDNA library was synthesized from total RNA prepared from the 
human glioblastoma cell line U-87 MG (ATCC, HTB-14), as previously described.7, 8 
Double-stranded cDNA was synthesized through conventional procedures and ligated 
into the EcoRI-XhoI site of λZAP II phage. The library size was over 1.0 × 106 
PFU/mL. 
 
2.3. Immunological screening using SEREX 
The screening method used in this study is the modification of a published 
procedure.(Matsutani et al., 2012) Escherichia coli XL1-Blue MRF’ was infected with 
Uni-ZAP XR phage containing a cDNA library, and cDNA expression was induced by 
blotting on nitrocellulose membranes pretreated with 10 mM 
isopropyl-β-D-thiogalactoside (IPTG; Wako Pure Chemicals, Osaka, Japan). After 
washing and blocking, membranes were exposed to 1:2000-diluted serum for 1 h. 
After washing, membranes were treated with 1:5000-diluted alkaline 
phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA). Positive reactions were developed using a color 
development solution containing 0.3 mg/mL of nitroblue tetrazolium chloride (Wako 
Pure Chemicals) and 0.15 mg/mL of 5-bromo-4-chloro-3-indolylphosphate (Wako 
Pure Chemicals). Positive clones were recloned twice to obtain monoclonality.  
 
2.4. Sequence analysis of identified antigens 
Monoclonal phage cDNA clones were converted into pBluescript phagemids by 
excision in vivo using the ExAssist helper phage (Stratagene, La Jolla, CA, USA). 
Plasmid DNA was obtained from the E. coli SOLR strain after transformation by 
phagemid. cDNA insertions were sequenced by dideoxy chain termination using DNA 
Sequencing BigDye Terminator Kits (Applied Biosystems, Foster City, CA, USA) and 
an ABI PRISM 3700 DNA Analyzer (Applied Biosystems). Sequences were screened 
for homology with identified genes or proteins within the public sequence database 
Muto et al.   Journal of Neuroimmunology, 0(0) 
using the NCBI-BLAST algorithm (http://www.ncbi.nlm.nih.gov/Blast.cgi/). 
 
2.5. Expression and purification of antigenic glutathione S-transferase (GST)-fusion 
proteins 
cDNA inserts of the clones incorporated in pBluescript were cleaved by EcoRI and 
XhoI and cloned into the EcoRI-XhoI site of pGEX-4 T-3, pGEX-4 T-2, and pGEX-4 
T-1 vectors (GE Healthcare Life Sciences, Pittsburgh, PA) that carry the expression of 
recombinant GST fusion proteins. E. coli JM109 cells (Nippon Gene, Toyama, Japan) 
containing pGEX clones (A600 = 0.3–0.5) were cultured in 200 mL of Luria broth, lysed 
through sonication, and centrifuged. GST fusion proteins in supernatants were 
purified by glutathione–Sepharose column chromatography according to the 
manufacturer’s instructions (GE Healthcare Life Sciences) and dialyzed. Proteins 
were confirmed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
 
2.6. Western blot analysis 
For Western blot analysis, three purified recombinant GST-fusion proteins, TLN1, 
DDX39 and NDRG1, were separated by SDS-polyacrylamide gel electrophoresis and 
electrically transferred onto a nitrocellulose membranes. The membrane was blocked 
with 0.5% nonfat dry milk in a buffer consisting of 20 mM Tris-HCl (pH 7.6), 137 mM 
NaCl and 0.1% Tween 20, and incubated with specific primary antibodies against 
TLN1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), DDX39 (TA303418, 
Origene, Rockville, MD) and NDRG1 (H-60, Santa Cruz Biotechnology). After 
incubation with horseradish peroxidase-conjugated secondary antibody, 
immunoreactivity was detected with the Immobilon (Merck Millipore, Darmstadt, 
Germany) as described previously (Hiwasa et al., 2000). 
 
2.7. Patients’ clinical information and healthy and disease controls 
Thirty-nine Japanese patients diagnosed with relapsing-remitting MS in our hospital 
between October 2003 and April 2014 were studied (31 women and 8 men; mean age, 
40.3 years). Patients fulfilled the revised 2005 McDonald’s criteria for MS,(Polman et 
al., 2005) and their clinical courses were a relapsing-remitting type. Eight patients 
were treated with interferon-α, one with fingolimod, and 30 had not been treated with 
immunomodulators or immunosuppressants to prevent relapse. 
Forty-three healthy participants (28 women and 15 men; mean age, 43.0 years) 
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matched for sex and age were used as normal control (NC). Thirty-five patients with 
Bickerstaff brainstem encephalitis (17 women and 18 men; mean age 43.4 years) 
matched for age were used as disease control (DC) (Table 1). Clinical condition of MS 
patients was monitored based on the Krutzke Expanded Disability Status Scale 
(EDSS) (Kurtzke, 1983). If the patient met the McDonald’s criteria (Polman et al., 
2005), clinical relapse was defined as an episode of neurological disturbance lasting 
at least 24 h. Oligoclonal IgG bands (OCBs) were determined by isoelectric focusing 
and were considered positive when they were only detected in CSF and comprised at 
least two bands. The IgG index represents (CSF IgG/serum IgG)/(CSF albumin/serum 
albumin) and was considered to be increased if it was >0.73. Serum samples were 
obtained from all 39 MS patients at the time of relapse and from 25 of these patients 
during remission. All the samples from patients and healthy participants were stored at 
−80°C until use.  
 
2.8. Measurement of serum antibodies against purified proteins by AlphaLISA  
To evaluate serum antibody levels, AlphaLISA, was performed in 384-well microtiter 
plates (white opaque OptiPlate™from PerkinElmer) containing 2.5 µL of 1:100-diluted 
serum and 2.5 µL of GST-fusion antigen proteins (10 µg/mL) or biotinylated synthetic 
peptides (400 ng/mL) in AlphaLISA buffer (25 mM HEPES, pH 7.4, 0.1% casein, 0.5% 
Triton X-100, 1 mg/mL dextran-500, and 0.05% Proclin-300). The reaction mixture 
was incubated at room temperature for 6–8 h; then, anti-human IgG-conjugated 
acceptor beads (2.5 µL at 40 µg/mL) and glutathione- or streptavidin-conjugated 
donor beads (2.5 µL at 40 µg/mL) were added and incubated at room temperature in 
the dark for 1–7 days. The plate was analyzed on an EnSpire Alpha microplate reader 
(PerkinElmer). 
 
2.9. Statistics 
Significant differences in percentages were determined by Fisher’s exact probability 
test. The comparison of values between the groups was analyzed by the 
Mann–Whitney U test. The Wilcoxon signed-rank test was applied to compare paired 
parameters. The relationship between Alpha count of MS patients’ sera, IgG index, 
and EDSS were estimated by the Spearman correlation coefficient test. Statistical 
analyses were performed using the SPSS statistical package (version 11.0.1J, SPSS 
Japan Inc., Tokyo, Japan). P < 0.05 was considered significant. 
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3. Results 
3.1. Seroreactive clones isolation by SEREX 
DNA sequence analysis and subsequent search for homology sequences in 
NCBI-accessible databases identified three independent clones, which showed 
remarkably high signal intensities, including talin1 (TLN1, NM_006289, Amino acid 
positions between 2153 and 2541 were cloned.), DEAD box polypeptide 39 (DDX39, 
NM_005804.3, Amino acid positions between 1 and 427 were cloned.), and N-myc 
downstream regulated gene 1 (NDRG1, NM_001135242.1 Amino acid positions 
between 338 and 394 were cloned.). Since we could purify TLN1, DDX39, and 
NDRG1 proteins by coliform bacilli and analyzed them by electrophoresis (Figure 1, 
lane (a)), the following analyses were conducted using all recombinant GST fusion 
proteins. To confirm the integrity of those purified proteins, Western blot analysis using 
commercial antibodies against TLN1, DDX39 and NDRG1 was performed. The results 
are shown in Figure 1, lane (b). Those proteins can be detected at expected size 
(TLN1, 68kDa; DDX39, 74kDa; and NDRG1, 32kDa).  
 
3.2. Autoantibodies against autoantigens isolated by SEREX in MS patients, NCs, and 
DCs 
To validate the sensitivity and specificity of novel candidate autoantigens in MS, we 
performed AlphaLISA for serum samples from 39 MS patients, 43 NCs, and 35 
DCs .The results of AlphaLISA with antigens are shown in Figure 2. The median 
(interquartile range) Alpha counts for anti-TLN1 antibodies in MS patients, NCs, and 
DCs were 1119 (1158), 683 (898), and 880 (1466.5), respectively. Meanwhile, the 
median (interquartile range) Alpha counts for anti-DDX39 antibodies in MS patients, 
NCs, and DCs were 28,241 (17,028), 21,135 (15,499), and 12,235 (24,621), 
respectively. The levels of anti-TLN1 antibody titers were significantly higher in MS 
patients than in NCs (P = 0.002) (Figure 2a), and the levels of anti-DDX39 antibody 
titers were also higher in sera from MS patients than in NCs (P = 0.01) (Figure 2b). 
However, the levels of anti-NDRG1 antibody titers were not significantly different 
between MS patients and NCs (data not shown). 
Moreover, we investigated the difference in antibody titers in the sera from MS 
patients during relapse phase and during remission phase. The median (interquartile 
range) Alpha counts for anti-TLN1 antibodies in MS patients were 1247 (953) during 
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relapse phase and 960 (997) during remission phase. On the other hand, the median 
(interquartile range) Alpha counts for anti-DDX39 antibodies in MS patients were 
25,583 (19,148) during relapse phase and 24,053 (16,503) during remission phase. 
Anti-TLN1 antibody titers were higher during relapse phase than remission phase (P = 
0.05) (Figure 3a), but anti-DDX39 (Figure 3b) and anti-NDRG1 (data not shown) 
antibody titers were similar between the two phases. 
 
3.3. Correlation between clinical information and antibody titers. 
We compared the titers of anti-TLN1, anti-DDX39, and anti-NDRG1 antibodies with 
clinical information including age, sex, disease duration, EDSS at sampling, and 
presence or absence of OCBs and IgG index. 
Anti-TLN1 antibody titers were significantly higher in OCB-negative MS patients 
than in OCB-positive MS patients (P = 0.03) (Figure 4a), but anti-DDX39 and 
anti-NDRG1 antibody titers were not significantly different in OCB-negative and 
OCB-positive MS patients (Figure 4b and data not shown). On the other hand, 
anti-TLN1 antibody titers were significantly higher in IgG index-negative MS patients 
than in IgG index-positive MS patients (P = 0.026) (Figure 4c), but anti-DDX39 and 
anti-NDRG1 antibody titers were not significantly different in IgG index-negative MS 
patients and in IgG index-positive MS patients (Figure 4d and data not shown). 
Moreover, a negative correlation was found between anti-TLN1 antibody titers and 
IgG index (P = 0.02) (Figure 4e), but not with anti-DDX39 or anti-NDRG1 antibodies 
(Figure 4f, data not shown). Age, sex, disease duration, and EDSS at sampling did not 
correlate with any antibody titers.  
 
4. Discussion 
In this study, we identified three proteins, TLN1, DDX39, and NDRG1, from sera of 
MS patients by SEREX, method that combines a molecular cloning using a cDNA 
expression library with serological typing and that was developed in order to identify 
antigenic targets for cancer immunotherapy on a genomic scale (Obata et al., 1999, 
Sahin et al., 1995). Recently, some autoantigens associated with autoimmune 
diseases including rheumatoid, systemic lupus erythematosus, and systemic sclerosis, 
were identified by SEREX or phage-display technology (Frampton et al., 2000, Kemp 
et al., 2002), thus demonstrating the usefulness of SEREX for identifying autoantigens 
associated with autoimmune diseases. Although many reports using other proteomics 
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technique have revealed the association between MS and clinical parameters 
including disease activity (O'Connor et al., 2003), SEREX method has been hardly 
applied for MS. 
TLN1 is an antiparallel actin-binding homodimer that links integrins to the actin 
cytoskeleton and is involved in the early steps of focal adhesion assembly (Campbell 
and Ginsberg, 2004, Critchley, 2000). VLA-4 (α4β1) is a key integrin in lymphocytes 
that interacts with endothelial vascular cell adhesion molecule 1 (VCAM-1) on blood 
vessels and stroma. TLN1 is a versatile VLA-4 affinity regulator implicated in both 
spontaneous and chemokine-triggered adhesion to VCAM-1 (Manevich et al., 2007) 
and regulates chemokine-induced T cell adhesion and migration. TLN1 also 
associated to a lymphocyte integrin LFA-1 (αLβ2), which plays a critical role in T cell 
trafficking and T cell adhesion to antigen presenting cells (Sampath et al., 1998).  
DDX39 was identified as a member of the DEAD-box RNA helicases and was 
shown to stimulate cancer cell growth (Sugiura et al., 2007). Because of a high 
sequence similarity to UAP56 (Shen et al., 2008, Shen et al., 2007), DDX39 has been 
suggested to play a role in pre-mRNA splicing and mRNA export (Sugiura et al., 2007). 
DDX39 was reported to be overexpressed in tumor cells, such as lung squamous cell 
cancer, gastrointestinal stromal tumor, urinary bladder cancer and malignant pleural 
mesothelioma cells (Kuramitsu et al., 2013), but it is unknown whether DDX39 is 
expressed in the CNS.  
NDRG1 is an intracellular protein that is thought to be involved in cell growth and 
differentiation and was identified as downregulated in tumors (Kurdistani et al., 1998, 
van Belzen et al., 1997) and as a metastasis suppressor gene (Bandyopadhyay et al., 
2003; Guan et al., 2000). As far as we know, it has never been described the 
association between anti-TLN1,-DDX39, and -NDRG1 antibodies and MS. 
Our study showed higher levels of the anti-TLN1 and anti-DDX39 antibodies in MS 
than in NC and DC, and only anti-TLN1 antibodies were higher during the relapse 
phase than during the remission phase in MS. Therefore, we hypothesized that 
anti-TLN1 antibodies were the only one involved in the attack of MS. 
In our clinical examination, OCB-positive MS patients were 39.1% (9/23), and 
anti-TLN1 antibodies were higher in OCB-negative MS patients than in OCB-positive 
MS patients (P = 0.03). The levels of anti-TLN1 antibodies in IgG index-negative MS 
patients were higher than in IgG index-positive MS patients (56% of our MS patients 
were IgG-positive). Moreover, we showed a negative correlation between the levels of 
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anti-TLN1 antibodies and IgG index in MS patients (P = 0.02).  
Interestingly, our clinical examination is similar to previous reports on OCB and 
IgG index of MS patients treated with natalizumab (Harrer et al., 2013; Mancuso et al., 
2014; von Glehn et al., 2012). Natalizumab is an effective monoclonal antibody 
therapy for the treatment of relapsing-remitting MS patients that interferes with 
immune cell migration into the CNS by binding to VLA-4 (Polman et al., 2006), thus 
causing a pronounced and sustained reduction of immune cells in CSF (Stuve et al., 
2006). Natalizumab is considered to substantially modulate both intrathecal polyclonal 
and oligoclonal IgG production. The mechanisms by which natalizumab interferes with 
the survival of plasma cells in CNS niches probably involves the dysregulation of 
prosurvival factors, comprising cytokines receptors and adhesion molecules, including 
the VLA-4 antigen (Mancuso et al., 2014). TLN1 maintains VLA-4 in a high affinity 
conformation, thereby promoting VLA-4 adhesion to VCAM-1 (Manevich et al., 2007) 
Anti-TLN1 antibodies may interfere with TLN1, thus leading to the disappearance of 
OCB and to the decrease of the IgG index shown in this study. Because TLN1 is a 
VLA-4 and LFA-1 integrin affinity regulator in T cells, we hypothesize that the 
migration of T lymphocytes into the CNS could also be reduced by blocking TLN-1 
function by anti-TLN1 antibodies.  
Other than VLA-4, LFA-1 also present on the surface on encephalitogenic T cells has 
been suggested to be involved in the pathogenesis of experimental allergic 
encephalomyelitis. Laschinger et al. showed that blocking LFA-1 on encephalitogenic 
T cells resulted in reduced number of T cells migrating across the vascular wall into 
the spinal cord parenchyma, and they concluded that encephalitogenic T cells use 
LFA-1 for transendothelial migration in spinal cord microvessels in vivo (Laschinger et 
al., 2002). Lyck et al. showed that the extracellular domain of ICAM-1, which is a 
ligand of LFA-1, is sufficient to support T-cell adhesion, whereas transendothelial 
migration was strictly dependent on the presence of the cytoplasmic tail of ICAM-1 
(Lyck et al., 2003). Moreover, previous reports showed that TLN1 activates LFA-1 and 
recruits it to the site of T cell receptor ligation, thereby stabilizing T cells–APC 
interaction (Shamri et al., 2005; ,Smith et al., 2005). Indeed, TLN1 is also implicated in 
LFA-1–dependent transendothelial migration and adhesion to APC. Therefore, if 
anti-TLN1 antibodies inhibit all the roles described for TLN1, TLN1 may constitute a 
novel therapeutic target in MS. 
In addition, in this study we revealed the specificity of anti-DDX39 antibody in the 
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sera of MS patients. Although the distribution and the function of DDX39 in human is 
still poorly understood, it was reported that DDX39 is highly expressed in CNS of 
Xenopus laevis, and that the Vad1, a DDX protein, regulates cryptococcal virulence 
via decrease of CD4+ cell and Th2 cytokines. Moreover, a DDX protein has been 
reported to modulate IL-12, IL-10 and TNF-α production by human monocytes. 
Although we could not show a correlation between clinical information and 
anti-DDX39 antibody titers, DDX protein may have some function on immunological 
process. 
We also found anti-NDRG1 antibodies in the serum from an MS patient, but the 
levels of anti-NDRG1 antibodies were not significantly higher than in NCs or DCs. We 
think it is unlikely that these antibodies have important roles on MS pathogenesis. 
NDRG1 is a cytoplasmic protein involved in stress responses, hormone responses, 
cell growth, and differentiation; mutations in this gene cause Charcot-Marie-Tooth 
disease type 4D (Gabrikova et al., 2013). Therefore, it cannot be totally excluded the 
possibility that this protein has some role on the demyelination in MS patients. 
This study has some limitations. First, we screened autoantigens using only one 
MS patient by SEREX. More autoantigens may be found using more MS patients. 
Second, the number of MS patients and DCs to validate the sensitivity and specificity 
might be insufficient. Further examination should be performed using more MS and 
DCs. Third, we considered the function of anti-TLN1 antibodies similar to the one of 
natalizumab. However, further findings on the function of anti-TLN1 antibodies in 
lymphocyte migration through the blood–brain barrier should be collected. Although 
we used the phage expression library constructed from a human glioblastoma cell line 
for immunoscreening by SEREX since it can contain oligodendroglial component, it is 
not the most appropriate one. A study using library constructed from cells originated 
from lymphocytes, oligodendrocytes, or human brain white matter should be 
performed. 
In conclusion, we found novel autoantibodies including anti-TLN1 antibodies in the 
serum of MS patients by SEREX and assumed that anti-TLN1 antibodies may have a 
protective action in MS pathogenesis. Therefore, anti-TLN1 antibodies could be used 
in the future to treat MS. 
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Figure captions 
Figure 1. Western blot validation using human recombinant proteins. 
Affinity-purified GST-tagged antigens were separated on SDS-polyacrylamide gels 
stained with Coomassie staining (lane (a)), and Western blotted using commercial 
antibodies against TLN1, DDX39, and NDRG1 (lane (b)). Western blot anlysis 
showed all recombinant GST fusion proteins can be detected at expected size (TLN1, 
68kDa; DDX39, 74kDa; and NDRG1, 32kDa). DDX39: DEAD box polypeptide 39; 
NDRG1: N-myc downstream regulated gene 1; TLN1: talin1. 
 
Figure 2. Anti-TLN1 and anti-DDX39 antibody titers in MS patients, NC, and DC 
groups.  
(a) Anti-TLN1 and (b) anti-DDX39 antibody titers measured by AlphaLISA and 
represented by Alpha count in MS patients, NCs, and DCs. They are plotted as dots 
with mean values indicated as bars. DC: disease control; DDX39: DEAD box 
polypeptide 39; MS: multiple sclerosis; NC: normal controls; TLN1: talin1. 
 
Figure 3. Anti-TLN1 and anti-DDX39 antibody titers in MS patients during 
relapse and remission phases. 
(a) Anti-TLN1 and (b) anti-DDX39 antibody titers measured by AlphaLISA are 
represented by Alpha count in MS patients during relapse and remission phases. 
They are plotted as dots with mean values indicated as bars. DDX39: DEAD box 
polypeptide 39; TLN1: talin1. 
 
Figure 4. Correlation of clinical information (OCB and IgG index) with serum 
anti-TLN1 and anti-DDX39 antibody titers. 
(a, b) Serum autoantibody (anti-TLN1 and anti-DDX39 antibodies) titers in 
OCB-positive and OCB-negative MS patients. (c, d) Serum autoantibody titers in MS 
patients with high (>0.73) and low (≤0.73) IgG index. (e, f) Correlation of IgG index 
with serum autoantibody titers. Serum anti-TLN1 (a, c, e) and anti-DDX39 antibodies 
(b, d, f) were measured by AlphaLISA and represented by Alpha count. In E and F, 
lines were obtained by linear regression, and Pearson's correlation coefficients (R2) 
are indicated. DDX39: DEAD box polypeptide 39; OCB: oligoclonal IgG bands; TLN1: 
talin1. 
 Table1. Clinical data of cases of multiple sclerosis, normal controls and other neurological diseases included in this study. 
  MS 
(n = 39) 
NC 
(n = 43) 
DC 
(n = 35) 
Male: Female  8 : 31 15 : 28 18:17 
Age, mean (SD), y 40.3 (11.5) 43.0 (9.4) 43.4 (15.5) 
Total disease duration, mean (SD), y 9.5 (9.6) — — 
EDSS score, median (range) 4.4 (1.0–9.5) — — 
OCB-positive patients (%) 39.1 — — 
Patients with high IgG index (>0.75) (%) 56.0 — — 
Therapy to prevent relapse  — — 
Interferon-β 8 — — 
Fingolimod 1 — — 
Nothing 30 — — 
NC, normal control; DC, disease control; OCB, oligoclonal IgG band; EDSS, Krutzke expanded disability status scale; SD, standard 
deviation; —, not available. 
 




